Shannon Jackilen, Tewoderos Selome, Garzotto Mark, Beer Tomasz M, Derenick Rhianna, Palma Amy, Farris Paige E
Oregon Health & Sciences University, Portland, OR 97239-3098, USA.
Am J Epidemiol. 2005 Aug 15;162(4):318-25. doi: 10.1093/aje/kwi203. Epub 2005 Jul 13.
Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of > or =7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.
观察性研究表明，使用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）可能与降低癌症风险有关。本病例对照研究的目的是阐明他汀类药物的使用与前列腺癌风险之间的关联。前列腺癌病例（n = 100）是在因前列腺活检而被转诊时招募的，频率年龄匹配的前列腺特异性抗原正常的门诊对照（n = 202）则从俄勒冈州波特兰市的退伍军人事务医疗中心招募。从电子药房数据库中获取了1997年5月至2004年8月期间任何他汀类药物使用情况的信息。记录了使用天数、他汀类药物类型、剂量和处方变化。根据使用天数和规定剂量计算每种他汀类药物类型的持续时间和强度。36%的病例和49%的对照有任何他汀类药物使用记录。在对其他潜在风险因素进行调整后，他汀类药物的使用与前列腺癌风险的显著降低相关（比值比 = 0.38，95%置信区间：0.21，0.69）。此外，在按Gleason评分分层的分析中，仅在Gleason评分为≥7的男性中维持了与他汀类药物使用的负相关（比值比 = 0.24，95%置信区间：0.11，0.53）。本病例对照研究的结果表明，他汀类药物可能降低总体前列腺癌的风险，特别是侵袭性更强的前列腺癌的风险。
